Baseline demographic and clinical characteristics of 31 patients with R/R CNS B-ALL and 158 patients with R/R B-ALL without CNS involvement
Characteristic . | Patients with CNS disease (n = 31) . | Patients without CNS disease (n = 158) . |
---|---|---|
Median age at CAR T-cell infusion (range), y | 46.5 (24-76) | 46 (18-81) |
Sex, n (%) | ||
Male | 18 (58.1) | 89 (56.3) |
Female | 13 (41.9) | 69 (43.7) |
ALL subtype, n (%) | ||
Ph− | 11 (35.5) | 86 (54.4) |
Ph+ | 14 (45.2) | 41 (25.9) |
Ph-like | 5 (16.1) | 29 (18.4) |
MPAL | 1 (3.2) | 2 (1.3) |
CNS disease status at initial diagnosis, n (%) | ||
CNS-1 | 24 (77.4) | 100 (63.3) |
CNS-2 | 2 (6.5) | 10 (6.3) |
CNS-3 | 1 (3.2) | 9 (5.7) |
Not assessed/unknown | 4 (12.9) | 39 (24.7) |
Median lines of therapy before CAR T-cell therapy, n (range) | 4 (2-12) | 3 (2-9) |
Previous therapies, n (%) | ||
Allogeneic HSCT | 18 (58.1) | 60 (38.0) |
Blinatumomab | 19 (61.3) | 93 (58.9) |
Inotuzumab ozogamicin | 12 (38.7) | 78 (49.5) |
Medullary disease status before apheresis, n (%) | ||
CR MRD-neg | 6 (19.3) | 22 (13.9) |
CR MRD-pos or unknown | 11 (35.5) | 40 (25.3) |
Active disease | 14 (45.2) | 80 (50.6) |
Unknown disease status | 0 (0) | 16 (10.1) |
CNS disease status before apheresis, n (%) | ||
CNS-1 | 0 (0) | 96 (60.8) |
CNS-2 | 15 (48.4) | 0 (0) |
CNS-3 | 16 (51.6) | 0 (0) |
Unknown status | 0 (0) | 62 (39.2) |
Characteristic . | Patients with CNS disease (n = 31) . | Patients without CNS disease (n = 158) . |
---|---|---|
Median age at CAR T-cell infusion (range), y | 46.5 (24-76) | 46 (18-81) |
Sex, n (%) | ||
Male | 18 (58.1) | 89 (56.3) |
Female | 13 (41.9) | 69 (43.7) |
ALL subtype, n (%) | ||
Ph− | 11 (35.5) | 86 (54.4) |
Ph+ | 14 (45.2) | 41 (25.9) |
Ph-like | 5 (16.1) | 29 (18.4) |
MPAL | 1 (3.2) | 2 (1.3) |
CNS disease status at initial diagnosis, n (%) | ||
CNS-1 | 24 (77.4) | 100 (63.3) |
CNS-2 | 2 (6.5) | 10 (6.3) |
CNS-3 | 1 (3.2) | 9 (5.7) |
Not assessed/unknown | 4 (12.9) | 39 (24.7) |
Median lines of therapy before CAR T-cell therapy, n (range) | 4 (2-12) | 3 (2-9) |
Previous therapies, n (%) | ||
Allogeneic HSCT | 18 (58.1) | 60 (38.0) |
Blinatumomab | 19 (61.3) | 93 (58.9) |
Inotuzumab ozogamicin | 12 (38.7) | 78 (49.5) |
Medullary disease status before apheresis, n (%) | ||
CR MRD-neg | 6 (19.3) | 22 (13.9) |
CR MRD-pos or unknown | 11 (35.5) | 40 (25.3) |
Active disease | 14 (45.2) | 80 (50.6) |
Unknown disease status | 0 (0) | 16 (10.1) |
CNS disease status before apheresis, n (%) | ||
CNS-1 | 0 (0) | 96 (60.8) |
CNS-2 | 15 (48.4) | 0 (0) |
CNS-3 | 16 (51.6) | 0 (0) |
Unknown status | 0 (0) | 62 (39.2) |
MPAL, mixed-phenotype acute leukemia; neg, negative; pos, positive.